HopeStage
Back to overview

Schizophrenia studies

Topics
More filters

Schizophrenia

Schizophrenia can affect how a person perceives reality, thinks and feels, sometimes involving hearing voices or holding unusual beliefs.

4505studies shown
Showing 1,693-1,704 of 4,505
Drug study icon
CompletedNCT02104752

Curcumin as a Novel Treatment to Improve Cognitive Dysfunction in Schizophrenia

What is this study about?

Researchers compared Curcumin and placebo to find out how the approaches affected memory, attention and other thinking skills in people with schizophrenia.

This study has finished and is no longer accepting participants.

In Los Angeles
SchizophreniaMedication studyAges 18–65
Countries
United States
Sponsor
VA Greater Los Angeles Healthcare System
Drug study icon
CompletedNCT01121042

Double Blind, Investigation of Ondansetron in Schizophrenia

Official study title

Double Blind, Placebo-Controlled, Randomised Investigation of Ondansetron in Schizophrenia

This study has finished and is no longer accepting participants.

In Melbourne
SchizophreniaMedication studyAges 18–65
Countries
Australia
Sponsor
Bayside Health
Other study type icon
CompletedNCT05056415

Effect and Cost-effectiveness of the Everyday Life Rehabilitation Intervention

Official study title

Effect and Cost-effectiveness of the 'Everyday Life Rehabilitation' Intervention: a Pragmatic RCT of Integrated, Recovery-focused Rehabilitation Within Sheltered and Supported Housing Facilities for People With Psychiatric Disabilities

This study has finished and is no longer accepting participants.

In Umeå
SchizophreniaInterventional studyAges 18+
Countries
Sweden
Sponsor
Umeå University
Drug study icon
CompletedNCT01163227

Effect of AQW051 on Cognitive Function in people with Chronic Stable Schizophrenia

Official study title

A Randomized, Double-blind, Placebo-controlled, Cross-over, Single-dose Study to Evaluate the Effects of AQW051 on Cognitive Function in Patients With Chronic Stable Schizophrenia Including a One Week Multiple-dose Extension to Assess the Persistence of Observed Effects and a Multiple-dose Cross Over Study in Non Smokers Only.

This study has finished and is no longer accepting participants.

Multiple locations, including Glendale
SchizophreniaMedication studyAges 18–55
Countries
United States
Sponsor
Novartis Pharmaceuticals
Behavioral study icon
CompletedNCT00137280

Implementing Effective, Collaborative Care for Schizophrenia (EQUIP-2)

Official study title

Implementing Effective, Collaborative Care for Schizophrenia

This study has finished and is no longer accepting participants.

Multiple locations, including Long Beach
SchizophreniaBehavioural studyAges 18+
Countries
United States
Sponsor
VA Office of Research and Development (Government agency)

Registry coverage

We gather information about mental health clinical trials from the public registries we index. Coverage is still expanding, so some studies may not appear yet.